BlackRock’s Moleculin Biotech MBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.37K | Hold |
25
| – | – | ﹤0.01% | 5548 |
|
|
2026
Q1 | $1.12K | Hold |
25
| – | – | ﹤0.01% | 5550 |
|
|
2025
Q4 | $1.64K | Hold |
25
| – | – | ﹤0.01% | 5400 |
|
|
2025
Q3 | $6.56K | Hold |
25
| – | – | ﹤0.01% | 5249 |
|
|
2025
Q2 | $3.74K | Hold |
25
| – | – | ﹤0.01% | 5286 |
|
|
2025
Q1 | $12.1K | Hold |
25
| – | – | ﹤0.01% | 5162 |
|
|
2024
Q4 | $21K | Hold |
25
| – | – | ﹤0.01% | 5094 |
|
|
2024
Q3 | $35.4K | Hold |
25
| – | – | ﹤0.01% | 4872 |
|
|
2024
Q2 | $43.9K | Hold |
25
| – | – | ﹤0.01% | 4890 |
|
|
2024
Q1 | $73.7K | Hold |
25
| – | – | ﹤0.01% | 4799 |
|
|
2023
Q4 | $162K | Sell |
25
-1
| -4% | -$4.15K | ﹤0.01% | 4691 |
|
|
2023
Q3 | $83.9K | Hold |
26
| – | – | ﹤0.01% | 4897 |
|
|
2023
Q2 | $114K | Sell |
26
-8
| -24% | -$42.2K | ﹤0.01% | 4872 |
|
|
2023
Q1 | $248K | Hold |
34
| – | – | ﹤0.01% | 4715 |
|
|
2022
Q4 | $272K | Sell |
34
-1
| -3% | -$8.44K | ﹤0.01% | 4766 |
|
|
2022
Q3 | $278K | Hold |
35
| – | – | ﹤0.01% | 4893 |
|
|
2022
Q2 | $384K | Hold |
35
| – | – | ﹤0.01% | 4859 |
|
|
2022
Q1 | $472K | Sell |
35
-2
| -5% | -$22.9K | ﹤0.01% | 4884 |
|
|
2021
Q4 | $510K | Buy |
37
+1
| +3% | +$17.7K | ﹤0.01% | 4864 |
|
|
2021
Q3 | $812K | Sell |
36
-1
| -3% | -$23.4K | ﹤0.01% | 4614 |
|
|
2021
Q2 | $1.02M | Buy |
37
+5
| +16% | +$136K | ﹤0.01% | 4508 |
|
|
2021
Q1 | $977K | Buy |
32
+31
| +3,100% | +$1.14M | ﹤0.01% | 4507 |
|
|
2020
Q4 | $34K | Hold |
1
| – | – | ﹤0.01% | 4716 |
|
|
2020
Q3 | $36K | Hold |
1
| – | – | ﹤0.01% | 4646 |
|
|
2020
Q2 | $42K | Sell |
1
-2
| -67% | -$94.8K | ﹤0.01% | 4602 |
|
|
2020
Q1 | $85K | Hold |
3
| – | – | ﹤0.01% | 4381 |
|
|
2019
Q4 | $127K | Buy |
3
+1
| +50% | +$46.8K | ﹤0.01% | 4402 |
|
|
2019
Q3 | $118K | Sell |
2
-1
| -33% | -$51.7K | ﹤0.01% | 4414 |
|
|
2019
Q2 | $141K | Buy |
3
+2
| +200% | +$109K | ﹤0.01% | 4419 |
|
|
2019
Q1 | $39K | Hold |
1
| – | – | ﹤0.01% | 4510 |
|
|
2018
Q4 | $54K | Hold |
1
| – | – | ﹤0.01% | 4465 |
|
|
2018
Q3 | $83K | Hold |
1
| – | – | ﹤0.01% | 4483 |
|
|
2018
Q2 | $89K | Buy |
+1
| New | +$81.9K | ﹤0.01% | 4475 |
|
|
2017
Q2 | – | Hold |
0
| – | -$21K | – | 5072 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 4610 |
|
Other funds holding MBRX
BlackRock's MBRX Position: Q2 2026 in Review
BlackRock held its Moleculin Biotech (MBRX) position steady in Q2 2026 at 25 shares worth $1.37K. The position accounts for ﹤0.01% of the portfolio, ranked #5548.
BlackRock first reported a position in MBRX in Q2 2018 and has held it in 33 quarters since. The position peaked at $1.02M in Q2 2021. 15 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.
- BlackRock held 25 shares of Moleculin Biotech worth $1.37K as of Q2 2026.
- BlackRock left its Moleculin Biotech share count unchanged in Q2 2026.
- Moleculin Biotech made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5548 holding.
- BlackRock first reported a position in Moleculin Biotech in Q2 2018 and has held it in 33 quarters since.
- BlackRock's Moleculin Biotech position peaked at $1.02M in Q2 2021.
- 15 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.